Peptide dose and/or structure in vaccines as a determinant of T cell responses

Vaccines

Volumn 2, Issue 3, 2014, Pages 537-548

  Leggatt, Graham R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Altered peptide ligands; Functional avidity; Peptide dose; Peptide structure; Peptide vaccines; T cell avidity; Vaccination

Indexed keywords

FLAGELLIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTHRITIS; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DOSE; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE DOSE; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE; TH1 TH2 BALANCE; VACCINATION; WART VIRUS;

EID: 85019466275     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2030537     Document Type: Review

References (80)

1. Paran, N.; Sutter, G. Smallpox vaccines: New formulations and revised strategies for vaccination. Hum. Vaccin 2009, 5, 824-831.
2. Lauring, A.S.; Jones, J.O.; Andino, R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010, 28, 573-579.
3. Bachmann, M.F.; Kalinke, U.; Althage, A.; Freer, G.; Burkhart, C.; Roost, H.; Aguet, M.; Hengartner, H.; Zinkernagel, R.M. The role of antibody concentration and avidity in antiviral protection. Science 1997, 276, 2024-2027.
4. Perrin, H.; Canderan, G.; Sekaly, R.P.; Trautmann, L. New approaches to design HIV-1 T-cell vaccines. Curr. Opin. HIV AIDS 2010, 5, 368-376.
5. Robinson, H.L. HIV/AIDS vaccines: 2007. Clin. Pharmacol. Ther. 2007, 82, 686-693.
6. Kearney, E.R.; Pape, K.A.; Loh, D.Y.; Jenkins, M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994, 1, 327-339.
7. Mount, A.; Koernig, S.; Silva, A.; Drane, D.; Maraskovsky, E.; Morelli, A.B. Combination of adjuvants: The future of vaccine design. Expert Rev. Vaccines 2013, 12, 733-746.
8. Riese, P.; Schulze, K.; Ebensen, T.; Prochnow, B.; Guzman, C.A. Vaccine adjuvants: Key tools for innovative vaccine design. Curr. Top. Med. Chem. 2013, 13, 2562-2580.
9. Bachmann, M.F.; Jennings, G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10, 787-796.
10. Correia-Pinto, J.F.; Csaba, N.; Alonso, M.J. Vaccine delivery carriers: Insights and future perspectives. Int. J. Pharm. 2013, 440, 27-38.
11. Trovato, M.; Krebs, S.J.; Haigwood, N.L.; de Berardinis, P. Delivery strategies for novel vaccine formulations. World J. Virol. 2012, 1, 4-10.
12. Blackburn, S.D.; Shin, H.; Haining, W.N.; Zou, T.; Workman, C.J.; Polley, A.; Betts, M.R.; Freeman, G.J.; Vignali, D.A.; Wherry, E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10, 29-37.
13. Barber, D.L.; Wherry, E.J.; Masopust, D.; Zhu, B.; Allison, J.P.; Sharpe, A.H.; Freeman, G.J.; Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439, 682-687.
14. Moskophidis, D.; Lechner, F.; Pircher, H.; Zinkernagel, R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362, 758-761.
15. Corradin, G.; Etlinger, H.M.; Chiller, J.M. Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice. J. Immunol. 1977, 119, 1048-1053.
16. Alexander-Miller, M.A.; Leggatt, G.R.; Sarin, A.; Berzofsky, J.A. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 1996, 184, 485-492.
17. Valkenburg, S.A.; Gras, S.; Guillonneau, C.; la Gruta, N.L.; Thomas, P.G.; Purcell, A.W.; Rossjohn, J.; Doherty, P.C.; Turner, S.J.; Kedzierska, K. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog. 2010, 6, e1001039.
18. Mitchison, N.A. Induction of immunological paralysis in two zones of dosage. Proc. R. Soc. Lond. B Biol. Sci. 1964, 161, 275-292.
19. Parish, C.R.; Liew, F.Y. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J. Exp. Med. 1972, 135, 298-311.
20. Gorse, G.J.; Keitel, W.; Keyserling, H.; Taylor, D.N.; Lock, M.; Alves, K.; Kenner, J.; Deans, L.; Gurwith, M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 2006, 24, 5950-5959.
21. Sirima, S.B.; Tiono, A.B.; Ouedraogo, A.; Diarra, A.; Ouedraogo, A.L.; Yaro, J.B.; Ouedraogo, E.; Gansane, A.; Bougouma, E.C.; Konate, A.T.; et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe Children. PLoS One 2009, 4, e7549.
22. Treanor, J.J.; Taylor, D.N.; Tussey, L.; Hay, C.; Nolan, C.; Fitzgerald, T.; Liu, G.; Kavita, U.; Song, L.; Dark, I.; et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28, 8268-8274.
23. Hangartner, L.; Zinkernagel, R.M.; Hengartner, H. Antiviral antibody responses: The two extremes of a wide spectrum. Nat. Rev. Immunol. 2006, 6, 231-243.
24. Lewis, J.J.; Janetzki, S.; Schaed, S.; Panageas, K.S.; Wang, S.; Williams, L.; Meyers, M.; Butterworth, L.; Livingston, P.O.; Chapman, P.B.; et al. Evaluation of CD8+ T-cell frequencies by the elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer 2000, 87, 391-398.
25. Luciani, F.; Sanders, M.T.; Oveissi, S.; Pang, K.C.; Chen, W. Increasing viral dose causes a reversal in CD8+ T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers. J. Immunol. 2013, 190, 36-47.
26. Amrani, A.; Verdaguer, J.; Serra, P.; Tafuro, S.; Tan, R.; Santamaria, P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000, 406, 739-742.
27. Slifka, M.K.; Whitton, J.L. Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat. Immunol. 2001, 2, 711-717.
28. Von Essen, M.R.; Kongsbak, M.; Geisler, C. Mechanisms behind functional avidity maturation in T cells. Clin. Dev. Immunol. 2012, 2012, doi:10.1155/2012/163453.
29. Fahmy, T.M.; Bieler, J.G.; Edidin, M.; Schneck, J.P. Increased TCR avidity after T cell activation: A mechanism for sensing low-density antigen. Immunity 2001, 14, 135-143.
30. Kersh, E.N.; Kaech, S.M.; Onami, T.M.; Moran, M.; Wherry, E.J.; Miceli, M.C.; Ahmed, R. TCR signal transduction in antigen-specific memory CD8 T cells. J. Immunol. 2003, 170, 5455-5463.
31. Gottschalk, R.A.; Corse, E.; Allison, J.P. TCR ligand density and affinity determine peripheral induction of FoxP3 in vivo. J. Exp. Med. 2010, 207, 1701-1711.
32. Alexander-Miller, M.A.; Leggatt, G.R.; Berzofsky, J.A. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 1996, 93, 4102-4107.
33. Sedlik, C.; Dadaglio, G.; Saron, M.F.; Deriaud, E.; Rojas, M.; Casal, S.I.; Leclerc, C. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J. Virol. 2000, 74, 5769-5775.
34. Foley, M.H.; Forcier, T.; McAndrew, E.; Gonzalez, M.; Chen, H.; Juelg, B.; Walker, B.D.; Irvine, D.J. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One 2014, 9, e87873.
35. Neveu, B.; Debeaupuis, E.; Echasserieau, K.; le Moullac-Vaidye, B.; Gassin, M.; Jegou, L.; Decalf, J.; Albert, M.; Ferry, N.; Gournay, J.; et al. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 2008, 48, 713-722.
36. Alexander-Miller, M.A.; Derby, M.A.; Sarin, A.; Henkart, P.A.; Berzofsky, J.A. Supraoptimal peptide-major histocompatibility complex causes a decrease in BC1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 1998, 188, 1391-1399.
37. Derby, M.A.; Snyder, J.T.; Tse, R.; Alexander-Miller, M.A.; Berzofsky, J.A. An abrupt and concordant initiation of apoptosis: Antigen-dependent death of CD8+ CTL. Eur. J. Immunol. 2001, 31, 2951-2959.
38. Ertelt, J.M.; Johanns, T.M.; Mysz, M.A.; Nanton, M.R.; Rowe, J.H.; Aguilera, M.N.; Way, S.S. Selective culling of high avidity antigen-specific CD4+ T cells after virulent salmonella infection. Immunology 2011, 134, 487-497.
39. Molldrem, J.J.; Lee, P.P.; Kant, S.; Wieder, E.; Jiang, W.; Lu, S.; Wang, C.; Davis, M.M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Investig. 2003, 111, 639-647.
40. Morgan, D.J.; Kreuwel, H.T.; Fleck, S.; Levitsky, H.I.; Pardoll, D.M.; Sherman, L.A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 1998, 160, 643-651.
41. Cawthon, A.G.; Lu, H.; Alexander-Miller, M.A. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: Correlation with CD8αβ versus CD8αα expression. J. Immunol. 2001, 167, 2577-2584.
42. Kroger, C.J.; Alexander-Miller, M.A. Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 2007, 122, 167-178.
43. Cawthon, A.G.; Alexander-Miller, M.A. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J. Immunol. 2002, 169, 3492-3498.
44. Hodge, J.W.; Chakraborty, M.; Kudo-Saito, C.; Garnett, C.T.; Schlom, J. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 2005, 174, 5994-6004.
45. Oh, S.; Hodge, J.W.; Ahlers, J.D.; Burke, D.S.; Schlom, J.; Berzofsky, J.A. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 2003, 170, 2523-2530.
46. Oh, S.; Perera, L.P.; Burke, D.S.; Waldmann, T.A.; Berzofsky, J.A. IL-15/IL-15ralpha-mediated avidity maturation of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA 2004, 101, 15154-15159.
47. Amoah, S.; Yammani, R.D.; Grayson, J.M.; Alexander-Miller, M.A. Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection. J. Immunol. 2012, 189, 638-645.
48. Kroger, C.J.; Alexander-Miller, M.A. Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high-and low-avidity effector cells. J. Immunol. 2007, 179, 748-751.
49. Zeh, H.J., 3rd; Perry-Lalley, D.; Dudley, M.E.; Rosenberg, S.A.; Yang, J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 1999, 162, 989-994.
50. Derby, M.; Alexander-Miller, M.; Tse, R.; Berzofsky, J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 2001, 166, 1690-1697.
51. Alexander-Miller, M.A. Differential expansion and survival of high and low avidity cytotoxic T cell populations during the immune response to a viral infection. Cell. Immunol. 2000, 201, 58-62.
52. Kroger, C.J.; Amoah, S.; Alexander-Miller, M.A. Cutting edge: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen. J. Immunol. 2008, 180, 5784-5788.
53. Bullock, T.N.; Mullins, D.W.; Engelhard, V.H. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 2003, 170, 1822-1829.
54. Hamilton, S.E.; Harty, J.T. Quantitation of CD8+ T cell expansion, memory, and protective immunity after immunization with peptide-coated dendritic cells. J. Immunol. 2002, 169, 4936-4944.
55. Kochenderfer, J.N.; Chien, C.D.; Simpson, J.L.; Gress, R.E. Maximizing CD8+ T cell responses elicited by peptide vaccines containing CPG oligodeoxynucleotides. Clin. Immunol. 2007, 124, 119-130.
56. Leggatt, G.R.; Narayan, S.; Fernando, G.J.; Frazer, I.H. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes. J. Leukoc. Biol. 2004, 76, 787-795.
57. Narayan, S.; Choyce, A.; Fernando, G.J.; Leggatt, G.R. Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity. Eur. J. Immunol. 2007, 37, 406-415.
58. Bullock, T.N.; Mullins, D.W.; Colella, T.A.; Engelhard, V.H. Manipulation of avidity to improve effectiveness of adoptively transferred CD8+ T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 2001, 167, 5824-5831.
59. Jordan, K.R.; McMahan, R.H.; Kemmler, C.B.; Kappler, J.W.; Slansky, J.E. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc. Natl. Acad. Sci. USA 2010, 107, 4652-4657.
60. Fazilleau, N.; McHeyzer-Williams, L.J.; Rosen, H.; McHeyzer-Williams, M.G. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat. Immunol. 2009, 10, 375-384.
61. Watson, A.M.; Mylin, L.M.; Thompson, M.M.; Schell, T.D. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J. Immunol. 2012, 189, 5549-5560.
62. Babatz, J.; Rollig, C.; Lobel, B.; Folprecht, G.; Haack, M.; Gunther, H.; Kohne, C.H.; Ehninger, G.; Schmitz, M.; Bornhauser, M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 2006, 55, 268-276.
63. Overwijk, W.W.; Tsung, A.; Irvine, K.R.; Parkhurst, M.R.; Goletz, T.J.; Tsung, K.; Carroll, M.W.; Liu, C.; Moss, B.; Rosenberg, S.A.; et al. Gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 1998, 188, 277-286.
64. Nicholson, L.B.; Greer, J.M.; Sobel, R.A.; Lees, M.B.; Kuchroo, V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995, 3, 397-405.
65. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
66. Kappos, L.; Comi, G.; Panitch, H.; Oger, J.; Antel, J.; Conlon, P.; Steinman, L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group. Nat. Med. 2000, 6, 1176-1182.
67. Iezzi, G.; Scotet, E.; Scheidegger, D.; Lanzavecchia, A. The interplay between the duration of TCR and cytokine signaling determines T cell polarization. Eur. J. Immunol. 1999, 29, 4092-4101.
68. Kumar, V.; Bhardwaj, V.; Soares, L.; Alexander, J.; Sette, A.; Sercarz, E. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Proc. Natl. Acad. Sci. USA 1995, 92, 9510-9514.
69. Mushtaq, K.; Chodisetti, S.B.; Rai, P.K.; Maurya, S.K.; Amir, M.; Sheikh, J.A.; Agrewala, J.N. Decision-making critical amino acids: Role in designing peptide vaccines for eliciting Th1 and Th2 immune response. Amino Acids 2014, 46, 1265-1274.
70. Evavold, B.D.; Allen, P.M. Separation of IL-4 production from th cell proliferation by an altered T cell receptor ligand. Science 1991, 252, 1308-1310.
71. Katsara, M.; Minigo, G.; Plebanski, M.; Apostolopoulos, V. The good, the bad and the ugly: How altered peptide ligands modulate immunity. Expert Opin. Biol. Ther. 2008, 8, 1873-1884.
72. Schaft, N.; Coccoris, M.; Drexhage, J.; Knoop, C.; de Vries, I.J.; Adema, G.J.; Debets, R. An altered gp100 peptide ligand with decreased binding by TCR and CD8α dissects T cell cytotoxicity from production of cytokines and activation of NFAT. Front. Immunol. 2013, 4, doi:10.3389/fimmu.2013.00270.
73. Fridkis-Hareli, M.; Reinherz, E.L. New approaches to eliciting protective immunity through T cell repertoire manipulation: The concept of thymic vaccination. Med. Immunol. 2004, 3, doi:10.1186/1476-9433-3-2.
74. Fridkis-Hareli, M.; Reche, P.A.; Reinherz, E.L. Peptide variants of viral CTL epitopes mediate positive selection and emigration of Ag-specific thymocytes in vivo. J. Immunol. 2004, 173, 1140-1150.
75. Franco, A.; Southwood, S.; Arrhenius, T.; Kuchroo, V.K.; Grey, H.M.; Sette, A.; Ishioka, G.Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 1994, 24, 940-946.
76. Iwanami, K.; Matsumoto, I.; Yoshiga, Y.; Inoue, A.; Kondo, Y.; Yamamoto, K.; Tanaka, Y.; Minami, R.; Hayashi, T.; Goto, D.; et al. Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide. Arthritis Res. Ther. 2009, 11, R167. doi:10.1186/ar2854.
77. Silano, M.; Vincentini, O.; de Vincenzi, M. Toxic, immunostimulatory and antagonist gluten peptides in celiac disease. Curr. Med. Chem. 2009, 16, 1489-1498.
78. Silano, M.; Vincentini, O.; Iapello, A.; Mancini, E.; de Vincenzi, M. Antagonist peptides of the gliadin T-cell stimulatory sequences: A therapeutic strategy for celiac disease. J. Clin. Gastroenterol. 2008, 42, S191-S192.
79. Aruna, B.V.; Ben-David, H.; Sela, M.; Mozes, E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis. Immunology 2006, 118, 413-424.
80. Lamont, A.G.; Sette, A.; Grey, H.M. Inhibition of antigen presentation in vitro and in vivo by MHC antagonist peptides. Int. Rev. Immunol. 1990, 6, 49-59.